Neuroprotective Effects of lncRNA EPB41L4A-AS1 Against Ischemic Stroke Injury Through Regulating Microglial State Transition and Ferroptosis via miR-214-3p/GPX4 Axis
Neurochemical Research · 2026
DOI: 10.1007/s11064-026-04827-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurochemical Research, 2026. Verfasst von Ying Guo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Affiliated Hospital of Jiangnan University, Wuxi, 214000, China. Hauptthemen laut MEDLINE: Ferroptosis, MicroRNAs, Microglia, RNA, Long Noncoding. Die Arbeit nennt 36 Literaturangaben.
Themen: Schlaganfall
Abstract (Originalsprache)
Long non-coding RNAs (lncRNAs) regulate microRNAs and their target genes to control key pathological processes after acute ischemic stroke (AIS). To investigate lncRNA EPB41L4A-AS1's role in microglial function via miR-214-3p/GPX4, and its clinical relevance as a prognostic indicator in AIS. EPB41L4A-AS1 levels were measured by RT-qPCR in 120 AIS patients and OGD/R-treated BV2 microglia. ELISA and western blot were employed to assess microglial state transition and ferroptosis in OGD/R-injured BV2 cells. A combination of RIP, RNA pull-down, and luciferase reporter assays were employed to validate the miRNA and gene targets regulated by EPB41L4A-AS1. Functional rescue assays were conducted by co-transfecting miR-214-3p with GPX4 to validate the regulatory relationship in vitro. EPB41L4A-AS1 was significantly downregulated in the serum of AIS patients, with lower levels predicting worse prognosis. Elevated EPB41L4A-AS1 expression substantially reduced pro-inflammatory markers (iNOS, TL-1β and TNF-α), but enhanced anti-inflammatory markers (Arg1 and IL-10) of OGD/R-injured BV2 cells. Meanwhile, the iron overload and lipid peroxidation in OGD/R cells were also improved. RIP, RNA pull-down, and luciferase reporter assays confirmed the specific binding of miR-214-3p to EPB41L4A-AS1 and GPX4. Upon EPB41L4A-AS1 overexpression, miR-214-3p mimic amplified the iron overload and oxidative stress and led to a pro-inflammatory state of BV2 cells under OGD/R conditions. Restoring GPX4 expression abrogated these observed effects. Lower serum EPB41L4A-AS1 correlates with poor prognosis in AIS patients. The mechanism underlying its neuroprotective effects against microglial state transition and ferroptosis was delineated through the miR-214-3p/GPX4 axis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Affiliated Hospital of Jiangnan University, Wuxi, 214000, China.
- Department of Cardiothoracic Vascular Surgery, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, 533000, China.
- Department of Neurology, General Hospital of Shaoxing Central Hospital Medical Consortium, Shaoxing, 312030, China.
- Department of Neurology, Jinan Central Hospital Affiliated to Shandong First Medical University, Xuanwu Jinan Hospital, Jinan, 250013, China.
- Department of Neurology, Hangzhou Red Cross Hospital, No. 208, Huan Cheng East Road, Gongshu District, Hangzhou, 310003, Zhejiang, China. Zhanghx_zj@163.com.
Zitieren
APA
Guo, Y., Yi, J., Fang, H., Zhang, Y., & Zhang, H. (2026). Neuroprotective Effects of lncRNA EPB41L4A-AS1 Against Ischemic Stroke Injury Through Regulating Microglial State Transition and Ferroptosis via miR-214-3p/GPX4 Axis. Neurochemical Research. https://doi.org/10.1007/s11064-026-04827-2
Vancouver
Guo Y, Yi J, Fang H, Zhang Y, Zhang H. Neuroprotective Effects of lncRNA EPB41L4A-AS1 Against Ischemic Stroke Injury Through Regulating Microglial State Transition and Ferroptosis via miR-214-3p/GPX4 Axis. Neurochemical Research. 2026. doi:10.1007/s11064-026-04827-2
BibTeX
@article{Guo2026,
author = {Guo, Ying and Yi, Jinyuan and Fang, Haitao and Zhang, Yu and Zhang, Haixiao},
title = {Neuroprotective Effects of lncRNA EPB41L4A-AS1 Against Ischemic Stroke Injury Through Regulating Microglial State Transition and Ferroptosis via miR-214-3p/GPX4 Axis},
journal = {Neurochemical Research},
year = {2026},
doi = {10.1007/s11064-026-04827-2}
}
EUVIMED